# SalioGen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/saliogen-therapeutics

- Industry: Biotechnology
- Headquarters: Burlington, US
- Website: www.saliogen.com
- Total disclosed funding: $95M
- Latest round: Series B (Nov 24, 2021)
- Investors on record: 9

## About

Based in Massachusetts, US, and founded in 2020, SalioGen Therapeutics, Inc. operates as a biotechnology company developing Gene Coding. Ray Tabibiazar serves as the CEO, and Chairman of the company as of 2021. In January 2022, SalioGen Therapeutics, Inc. raised USD 115 million in series B funding co-led by new investors EPIQ Capital Group and GordonMD Global Investments, with participation from other new investors.

The company is the developer of Gene Coding, a genetic medicine platform that uses its Exact DNA Integration Technology (EDIT) to give patients with inherited disorders, effective and broadly applicable non-viral gene therapy. The company's mammalian-derived genome editing technology will be employed in possibly curative nonviral gene therapy, allowing the healthcare industry to cure people in need.

The company plans to use the series B funding received in January 2022 to expand its team, establish manufacturing and automation capabilities critical for Gene Coding, and accelerate the advancement of its preclinical programs.

## Funding rounds

- Series B, Nov 24, 2021, $75M — T Rowe Price, Fidelity Investments, PBM Capital Group, Cystic Fibrosis Foundation, D1 Capital Partners, EPIQ Capital Group, SymBiosis LLC, GordonMD Global Investments, Retinal Degeneration Fund
- Series A, Feb 4, 2021, $20M — PBM Capital Group

## Investors

- PBM Capital Group (https://capitalatlas.ai/funds/pbm-capital-group) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Cystic Fibrosis Foundation — Series B
- D1 Capital Partners (https://capitalatlas.ai/funds/d1-capital-partners) — Series B
- EPIQ Capital Group — Series B
- SymBiosis LLC — Series B
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series B
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series B